Antiangiogenic Activity of the Selective Cyclooxygenase 2 Inhibitor Rofecoxib in Human Colorectal Cancer Liver Metastases

Gut - United Kingdom
doi 10.1136/gut.2005.090571
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Etodolac, a Selective Cyclooxygenase-2 Inhibitor, Inhibits Liver Metastasis of Colorectal Cancer Cells via the Suppression of MMP-9 Activity

International Journal of Molecular Medicine
MedicineGenetics
2006English

Antitumor Activity of the Selective Cyclooxygenase-2 Inhibitor, Celecoxib, on Breast Cancer in Vitro and in Vivo

Cancer Cell International
Cancer ResearchOncologyGenetics
2012English

Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis

Archives of Internal Medicine
2000English

Differential Expression of Cyclooxygenase 2 in Human Colorectal Cancer Reply

Gut
Gastroenterology
2000English

Systemic Treatment of Liver Metastases From Colorectal Cancer

Therapeutic Advances in Medical Oncology
Oncology
2013English

Colorectal Liver Metastases

Journal of Gastrointestinal Surgery
SurgeryGastroenterology
2012English

Over-Expression of Cyclooxygenase-2 in Colorectal Cancer Patients

Asian Pacific Journal of Cancer Prevention
2019English

Distinct Pattern of Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 mRNA Expression in Human Colorectal Cancer and Liver Metastases

British Journal of Cancer
Cancer ResearchOncology
1995English

Interleukin-12 Prevents Colorectal Cancer Liver Metastases in Mice

OncoTargets and Therapy
OncologyPharmacology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy